STOCK TITAN

Gritstone bio, Inc. - $GRTS STOCK NEWS

Welcome to our dedicated page for Gritstone bio news (Ticker: $GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gritstone bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gritstone bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.46%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.32%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.55%
Tags
none
Gritstone bio, Inc.

Nasdaq:GRTS

GRTS Rankings

GRTS Stock Data

90.05M
90.55M
2.3%
40.27%
9.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
EMERYVILLE

About GRTS

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.